Renee Gala Sells 2,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Renee Gala sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $243.03, for a total transaction of $486,060.00. Following the sale, the chief executive officer directly owned 143,394 shares in the company, valued at $34,849,043.82. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $245.80 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The stock has a 50-day moving average of $249.37 and a two-hundred day moving average of $223.73. The stock has a market cap of $15.96 billion, a P/E ratio of 16.95, a P/E/G ratio of 0.22 and a beta of 0.36. Jazz Pharmaceuticals PLC has a one year low of $123.88 and a one year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($8.25) earnings per share. As a group, research analysts predict that Jazz Pharmaceuticals PLC will post 21.5 EPS for the current year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Royal Bank of Canada grew its position in shares of Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after buying an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after buying an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after buying an additional 7,954 shares during the last quarter. Focus Partners Wealth increased its position in Jazz Pharmaceuticals by 3.4% during the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. lifted its stake in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several recent research reports. Sanford C. Bernstein reissued a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. UBS Group increased their price target on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research report on Friday. Piper Sandler boosted their price objective on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Needham & Company LLC upped their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. Finally, TD Cowen raised their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $286.72.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.